Fisher & Paykel Healthcare Corporation Ltd (FPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fisher & Paykel Healthcare Corporation Ltd (FPH) has a cash flow conversion efficiency ratio of 0.124x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$243.82 Million) by net assets (AU$1.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fisher & Paykel Healthcare Corporation Ltd - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Fisher & Paykel Healthcare Corporation Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Fisher & Paykel Healthcare Corporation Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fisher & Paykel Healthcare Corporation Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sterling Construction Company Inc
NASDAQ:STRL
|
0.167x |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
0.047x |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
0.119x |
|
Penumbra Inc
NYSE:PEN
|
0.043x |
|
Gaming & Leisure Properties
NASDAQ:GLPI
|
0.048x |
|
LIG Nex1 Co Ltd
KO:079550
|
-0.343x |
|
Samsung Fire & Marine Insurance
KO:000810
|
0.068x |
|
HDFC Asset Management Company Limited
NSE:HDFCAMC
|
0.155x |
Annual Cash Flow Conversion Efficiency for Fisher & Paykel Healthcare Corporation Ltd (2000–2025)
The table below shows the annual cash flow conversion efficiency of Fisher & Paykel Healthcare Corporation Ltd from 2000 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | AU$1.89 Billion | AU$548.60 Million | 0.290x | +18.83% |
| 2024-03-31 | AU$1.76 Billion | AU$429.60 Million | 0.244x | +79.84% |
| 2023-03-31 | AU$1.64 Billion | AU$222.85 Million | 0.136x | -29.66% |
| 2022-03-31 | AU$1.56 Billion | AU$300.36 Million | 0.193x | -53.03% |
| 2021-03-31 | AU$1.40 Billion | AU$574.83 Million | 0.411x | +24.59% |
| 2020-03-31 | AU$943.25 Million | AU$311.18 Million | 0.330x | +18.94% |
| 2019-03-31 | AU$876.75 Million | AU$243.19 Million | 0.277x | -14.77% |
| 2018-03-31 | AU$716.08 Million | AU$233.05 Million | 0.325x | +11.24% |
| 2017-03-31 | AU$606.29 Million | AU$177.38 Million | 0.293x | +9.61% |
| 2016-03-31 | AU$488.89 Million | AU$130.49 Million | 0.267x | -12.68% |
| 2015-03-31 | AU$471.19 Million | AU$144.02 Million | 0.306x | +27.13% |
| 2014-03-31 | AU$406.12 Million | AU$97.64 Million | 0.240x | +29.05% |
| 2013-03-31 | AU$372.23 Million | AU$69.35 Million | 0.186x | -12.33% |
| 2012-03-31 | AU$348.15 Million | AU$73.98 Million | 0.212x | +27.43% |
| 2011-03-31 | AU$313.29 Million | AU$52.24 Million | 0.167x | -54.10% |
| 2010-03-31 | AU$293.16 Million | AU$106.51 Million | 0.363x | +44.63% |
| 2009-03-31 | AU$204.30 Million | AU$51.32 Million | 0.251x | +28.07% |
| 2008-03-31 | AU$195.66 Million | AU$38.38 Million | 0.196x | -32.64% |
| 2007-03-31 | AU$193.51 Million | AU$56.35 Million | 0.291x | -27.95% |
| 2006-03-31 | AU$203.99 Million | AU$82.44 Million | 0.404x | +16.92% |
| 2005-03-31 | AU$192.03 Million | AU$66.38 Million | 0.346x | +26.01% |
| 2004-03-31 | AU$191.22 Million | AU$52.46 Million | 0.274x | +15.11% |
| 2003-03-31 | AU$192.82 Million | AU$45.95 Million | 0.238x | -26.99% |
| 2002-03-31 | AU$171.88 Million | AU$56.10 Million | 0.326x | +8.06% |
| 2001-03-31 | AU$152.09 Million | AU$45.94 Million | 0.302x | +27.59% |
| 2000-03-31 | AU$191.42 Million | AU$45.32 Million | 0.237x | -- |
About Fisher & Paykel Healthcare Corporation Ltd
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The com… Read more